| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A look at new models to support vaccine research and development
|
Gold, David
|
|
2001
|
20 |
S1 |
p. S94-S95
2 p.
|
article
|
| 2 |
Alternative vaccine strategies to prevent serogroup B meningococcal diseases
|
Poolman, Jan
|
|
2001
|
20 |
S1 |
p. S24-S26
3 p.
|
article
|
| 3 |
Analysis of factors influencing vaccine uptake from various perspectives
|
Aston, Robert
|
|
2001
|
20 |
S1 |
p. S1-
1 p.
|
article
|
| 4 |
Analysis of factors influencing vaccine uptake: perspective from Spain
|
Alonso, José A.Navarro
|
|
2001
|
20 |
S1 |
p. S13-S15
3 p.
|
article
|
| 5 |
Analysis of factors influencing vaccine uptake: perspectives from Belgium
|
Swennen, B.
|
|
2001
|
20 |
S1 |
p. S5-S7
3 p.
|
article
|
| 6 |
Benefit and risk of vaccination as seen by the general public and the media
|
Cookson, Clive
|
|
2001
|
20 |
S1 |
p. S85-S88
4 p.
|
article
|
| 7 |
Business perspectives of a European vaccine manufacturer
|
Vandersmissen, Walter
|
|
2001
|
20 |
S1 |
p. S104-S106
3 p.
|
article
|
| 8 |
Detection of adverse events: what are the current sensitivity limits during clinical development?
|
Fritzell, Bernard
|
|
2001
|
20 |
S1 |
p. S47-S48
2 p.
|
article
|
| 9 |
Developing vaccines involving new technologies to ensure safety and timely licensure
|
Hessel, Luc
|
|
2001
|
20 |
S1 |
p. S70-S72
3 p.
|
article
|
| 10 |
Factors influencing vaccine uptake in Germany
|
Schmitt, Heinz-J.
|
|
2001
|
20 |
S1 |
p. S2-S4
3 p.
|
article
|
| 11 |
Factors influencing vaccine uptake in Italy
|
Bonanni, Paolo
|
|
2001
|
20 |
S1 |
p. S8-S12
5 p.
|
article
|
| 12 |
Feasibility of improving safety beyond certain limits in clinical trials
|
Keller-Stanislawski, Brigitte
|
|
2001
|
20 |
S1 |
p. S45-S46
2 p.
|
article
|
| 13 |
How to improve communication on vaccine issues at the national level?
|
Siegrist, Claire-Anne
|
|
2001
|
20 |
S1 |
p. S98-S100
3 p.
|
article
|
| 14 |
How to improve communication on vaccine safety at international level?
|
Duclos, Philippe
|
|
2001
|
20 |
S1 |
p. S96-S97
2 p.
|
article
|
| 15 |
Immunopathogenesis of vaccine-enhanced RSV disease
|
Openshaw, Peter J.M.
|
|
2001
|
20 |
S1 |
p. S27-S31
5 p.
|
article
|
| 16 |
Improving vaccine safety through the use of immunisation registers and bar code labelled vaccines
|
Heijbel, Harald
|
|
2001
|
20 |
S1 |
p. S75-S77
3 p.
|
article
|
| 17 |
Lessons learned concerning vaccine safety
|
Plotkin, Stanley A.
|
|
2001
|
20 |
S1 |
p. S16-S19
4 p.
|
article
|
| 18 |
Maternal immunization: the influence of liability issues on vaccine development
|
Paradiso, Peter R.
|
|
2001
|
20 |
S1 |
p. S73-S74
2 p.
|
article
|
| 19 |
Perception of risk of vaccine adverse events: a historical perspective
|
Spier, R.E.
|
|
2001
|
20 |
S1 |
p. S78-S84
7 p.
|
article
|
| 20 |
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
|
Miller, E.
|
|
2001
|
20 |
S1 |
p. S58-S67
10 p.
|
article
|
| 21 |
Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization
|
Glueck, Reinhard
|
|
2001
|
20 |
S1 |
p. S42-S44
3 p.
|
article
|
| 22 |
Predictive value of pre-clinical work for vaccine safety assessment
|
Verdier, François
|
|
2001
|
20 |
S1 |
p. S21-S23
3 p.
|
article
|
| 23 |
Primum non nocere in vaccinology
|
Burgio, G.R.
|
|
2001
|
20 |
S1 |
p. S55-S57
3 p.
|
article
|
| 24 |
Regulating vaccines involving new technologies to ensure safety and timely licensure — the challenge
|
Haase, M.
|
|
2001
|
20 |
S1 |
p. S68-S69
2 p.
|
article
|
| 25 |
Respiratory syncytial virus vaccine development
|
Crowe Jr., James E.
|
|
2001
|
20 |
S1 |
p. S32-S37
6 p.
|
article
|
| 26 |
Rise in popularity of complementary and alternative medicine: reasons and consequences for vaccination
|
Ernst, E.
|
|
2001
|
20 |
S1 |
p. S90-S93
4 p.
|
article
|
| 27 |
Statistical assessment of the association between vaccination and rare adverse events post-licensure
|
Andrews, N.J.
|
|
2001
|
20 |
S1 |
p. S49-S53
5 p.
|
article
|
| 28 |
The future of vaccines: an industrial perspective
|
Gréco, Michel
|
|
2001
|
20 |
S1 |
p. S101-S103
3 p.
|
article
|
| 29 |
The medical scientist working with the media for the public good
|
Aston, Robert
|
|
2001
|
20 |
S1 |
p. S89-
1 p.
|
article
|
| 30 |
What are the limits of adjuvanticity?
|
Del Giudice, Giuseppe
|
|
2001
|
20 |
S1 |
p. S38-S41
4 p.
|
article
|
Journal description